Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The outer membrane of Gram-negative bacteria is a specialized asymmetric bilayer where the outer leaflet is primarily composed of lipopolysaccharides (LPS) and the membrane is embedded with various outer membrane proteins (OMPs) (Raetz & Whitfield, 2002, Annual Review of Biochemistry). The LPS core glycolipid is a conserved region that maintains the structural integrity of the membrane and acts as a permeability barrier against toxic compounds, including many antibiotics (Nikaido, 2003, Microbiology and Molecular Biology Reviews). OMPs, such as porins and the BAM complex, are critical for nutrient acquisition and the proper assembly of the cell envelope (Knowles et al., 2009, Nature Reviews Microbiology). In the context of disease, LPS acts as a potent endotoxin, triggering an overactive immune response that can lead to life-threatening sepsis and septic shock (Opal, 2010, Journal of Infectious Diseases). Therapeutic agents targeting these components include polymyxins, which disrupt the membrane by binding to LPS, and novel inhibitors like murepavadin that target OMP-related transport systems (Landman et al., 2008, Clinical Microbiology Reviews; Martin-Loeches et al., 2018, Expert Opinion on Investigational Drugs). These targets are of high clinical importance for addressing multi-drug resistant Gram-negative pathogens.
Disruption of the bacterial outer membrane through binding to lipopolysaccharides; inhibition of outer membrane protein assembly via the BAM complex; inhibition of lipopolysaccharide transport via the Lpt pathway; neutralization of endotoxin-induced inflammatory responses.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipopolysaccharide core glycolipid and outer membrane proteins (LPS/OMP).